- Case Report
- Open Access
Inflammatory myofibroblastic tumor of the bladder – an unexpected case coexisting with an ovarian teratoma
© Dobrosz et al.; licensee BioMed Central Ltd. 2014
- Received: 9 April 2014
- Accepted: 21 May 2014
- Published: 15 July 2014
Inflammatory myofibroblastic tumors (IMTs) mainly occur in children and young adults, usually in the first two decades of life. IMT-type tumors belong to neoplasms of an intermediate biologic potential with considerable rate of local recurrence and in some cases that able to create metastases. Presented case is the first IMT coexisting with the other neoplasm. In our paper we are going to present a peculiar case of an IMT of the bladder coexisting with an ovarian teratoma, and to discuss its pathogenesis, histological picture and differential diagnosis. A 19-year-old female was admitted to the Gynecological Department and during the surgery, two independent, non-adjacent tumors were found. To settle the diagnosis, a FISH examination with the ALK1 break apart probe was carried out. It confirmed the rearrangement of the chromosome 2p23. Morphologic and immunophenotypic similarities between an IMT and other malignant tumors of the bladder may lead to diagnostic errors and an unnecessary radical cystectomy as a result. The therapy of choice is only total excision of the tumor.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1937487606122622
- Inflammatory Myofibroblastic Tumor
- Bladder neoplasm
- Fish analysis
Inflammatory myofibroblastic tumors (IMTs) mainly occur in children and young adults, usually in the first two decades of life. The most frequent sites of these tumors are the lungs, the peritoneum and the mesentery [1, 2]. IMTs are very rarely localized in the bladder, so they need to be differentiated from other bladder tumors , mainly rhabdomyosarcomas and leiomyosarcomas.
Tumors of non-epithelial origin account for about 2-5% of all neoplasmatic tumors of the bladder: rhabdomyosarcomas appear most frequently in children under the age of ten, while leiomyosarcomas are most frequent in adults . In our paper we are going to present a peculiar case of an IMT coexisting with an ovarian teratoma, and discuss its pathogenesis, histological picture and differential diagnosis.
A 19-year-old female was admitted to the Gynecological Department of the Municipal Hospital due to 3-month-long pain in the hypogastrium. An ultrasonographic study revealed a tumor on the left ovary corresponding to a teratoma with hypoechogenic structure; it just seemed that the tumor infiltrated the wall of the bladder and grew into its lumen. However, during the surgery, two independent, non-adjacent tumors were found. One of these was a tumor on the left ovary, 45 mm in diameter. The tumor had a well-defined capsule, and macroscopically was diagnosed as a teratoma. The second lesion was a hard tumor 30 × 40 mm, well circumscribed, which was deforming the anterior wall of the bladder, and growing into its lumen. The left appendices and the uterus were normal. An insignificant amount of transudate fluid was found on the pelvic floor. The affected ovary was excised, and then, the anterior wall of the bladder was incised and a solid tumor of 40 × 30 mm was removed.
IHC staining (type of cytokeratines) IMT presented in article
Cases of urinary bladder IMT
No of case
Immunophenotype of tumor cells
No of (art.)
6 × 3 cm
Weight loss, hematuria, abdominal pain
CK(+), VIM(+), ALK-1(+)
Proliferation of fusiform myoepithelial cells
2 months without recurrence
6.4 × 4.5 × 3,8 cm
Fever, diffuse myalgia, weight loss, anemia,
CK(-), SMA(+), MyoD1(-), ALK-1(+)
2 months without recurrence
7.5 × 4.5 cm
Duration, gross hematuria, bacteruria
CK(-), VIM(+), S-100(-), CD68(+)
1 year without recurrence
2.4 × 2.3 × 2.2 cm
Hematuria, abdominal pain
CK8/18/19 focally(+), S100(-),ALK1(+), MyoD1(-), CD117(-)
Low grade leiomyosarcoma
3 years without recurrence
Postoperative spindle cell nodule (PSCN) but excluded because of absence of previous surgery
6 × 5 cm
Hematuria, dots in urine, burning micturition, weakness, abdominal pain
CK 20(-), SMA(+), VIM(+), ALK-1(+), DES(-), CD117(-)
15 months without recurrence
CK(-),SMA(+), VIM(+), ALK-1(+), DES(+), Myogenin(-)
1 year without recurrence
Hematuria, abdominal pain
SMA(+), VIM(+), ALK-1(+), DES(+), Myoglobin(-), CD34 (-), S-100 (-)
13 months without recurrence
The first case of an IMT in the bladder was described by Roth in 1980 . The origin of this tumor was a matter of a long debate; some authors maintained that an IMT is a consequence of an inflammation in the bladder, while others regarded it as a neoplastic lesion. The Epsten-Barr virus, the human herpes virus HHV8, bacteria such as Campylobacter equi, Campylobacter jejuni, Escherichia coli, trauma, radio- and steroidotherapy were considered to be causative factors [1, 2]. In some articles, Hepatitis C, HIV and TB infections prior to the development of pseudotumors have been documented [2, 15]. Fangusaro at al. described two cases of IMT following hematopoetic stem cell transplantation. Both patients received total body irradiation in preparation for the transplant. These two cases suggest radiation as a possible underlying cause of IMT . However, more recent research has showed that an IMT is most probably a neoplasm rather than an inflammatory pseudotumor; both rearrangement of 2p23 chromosome as well as sporadic local invasion or metastases speak in favor of neoplasmatic origin of the tumor [17, 18].
Teratomas are neoplasms that arise from pluripotent cells and can differentiate along one or more embryonic germ lines [19, 20]. Mature teratomas of the ovary are one of the most common benign ovarian neoplasms, accounting for approximately 10-20% of all ovarian tumors. Teratoma may occur at any age in women, but predominantly occurs in younger patients (20–40 years old) . Mature ovarian teratomas are benign ovarian germ cell tumors that usually occur with a normal karyotype. There are very few reports describing chromosomal abnormalities in these tumors, none of which are recurrent. The Ding Y study in 2011 was the first to demonstrate the differential profile of 16 miRNAs in mature ovarian teratomas. An aberrant expression of miRNAs may be essential for the pathogenesis of mature ovarian teratomas .
An IMT may occur in the bladder at any age (from childhood to old age) [23, 24]. This rare disease does not usually cause pain; the most frequent symptoms are severe hematuria, sometimes anuria and a palpable tumor. The tumor may be localized in any region of the bladder, however the trigone of the bladder has never been affected, apart of the cases where the tumor arose in the posterior wall of the bladder and secondarily infiltrated the trigone . The size of the tumor is variable – from several centimeters up to 37.5 cm . Obviously, it is not possible to distinguish an IMT from malignant tumors of the bladder with diagnostic methods such as an RTG or endoscopy. Macroscopically, these tumors are well circumscribed, light and soft; the cut surface is smooth, occasionally opalescent, without hemorrhagic foci or necrosis .
Histologically, it is possible to distinguish three types of these tumors: the vascular-myxoidal type, which can resemble nodular fasciitis or granulomatous tissue; the solid, spindle-cell type, which resembles a fibrous histiocytoma or tumor originating from smooth muscle or a low-cellular-fibrous, which imitates desmoids or a scar [2, 8, 26].
The key criteria in IMT diagnostics are: proliferation of myoepithelial spindle cells accompanied by lymphocytic infiltration of tumor stroma, the positive immunohistochemical reaction to ALK-1, vimentin and cytokeratin [27, 28], and finally ALK1 gene rearrangement confirmed cytogenetically or by FISH method. It shows the rearrangement of the ALK gene in the population of spindle cells in an IMT . The ALK gene is located on the 2p23 chromosome; it encodes the ALK protein, the tyrosine kinase receptor. This method is a very sensitive tool used to differentiate an IMT from other spindle-cell tumors of the bladder. In IMT tumors, the positive immunohistochemical reaction with an antibody against ALK-1 is observed in more than 60% cases, while in the FISH method it is observed in almost 70% of the cases. Overexpression of this gene is also observed in anaplastic large cell lymphoma . Some IMTs show an expression of cytokeratins, SMA or desmin [18, 27]. Myogenin, a rhabdomyosarcoma marker, allows this tumor to be excluded .
Morphologic and immunophenotypic similarities between an IMT and other malignant tumors of the bladder may lead to diagnostic errors and an unnecessary radical cystectomy as a result.
The misdiagnosis of an IMT as a rhabdomyosarcoma, a leiomyosarcoma or a sarcomatoid urothelial carcinoma, and as a result, unnecessary radical surgery, adjuvant therapy and its complications, is a major problem of contemporary IMT diagnostics.
IMT-type tumors belong to neoplasms of an intermediate biologic potential with a considerable rate of local recurrence and in some cases they are able to create metastases . In the case described in this paper, the presence of a large necrosis in the central portion of the tumor, mitotic activity and the presence of aneuploidal cells (seen in cytofluorometry) suggest a more aggressive type of IMT. The therapy of choice is the total excision of the tumor, a radical cystectomy is not necessary [32, 33].
The study (No 1340143-46) was performed in accordance with the Declaration of Helsinki and the protocol was approved by the local Human Research Ethics Committee. Informed consent was obtained from the patient for publication of this case report and any accompanying images.
- Coffin CM, Humphrey PA, Dehner LP: Extrapulmonary inflammatory myofibroblastic tumor: a clinical and pathological survey. Semin Diagn Pathol. 1998, 15: 85-101.PubMedGoogle Scholar
- Coffin CM, Watterson J, Priest JR, Dehner L: Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor): a clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol. 1995, 19: 859-872. 10.1097/00000478-199508000-00001.PubMedView ArticleGoogle Scholar
- Ro JY, Ayale AG, Ordonez NG: Pseudosarcomatous fibromyxoid tumor of the urinary bladder. Am J Clin Pathol. 1986, 86: 583-590.PubMedGoogle Scholar
- Juan R: Urinary bladder. Rosai and Ackerman's surgical pathology, Volume 1. Edited by: Houston M. 2004, St Louis: Mosby, 1317-1359. 9Google Scholar
- Filho JB, Martines JA, Martines BM, Cavalcanti M, Cerri GG, Castro CC: Inflammatory myofibroblastic tumor of the bladder in a child: a case report. Radiologia Brasileira. 2012, 45 (4): 230-232. 10.1590/S0100-39842012000400010.View ArticleGoogle Scholar
- Hoene KA, Kaufman MR, Cates JM, Chang SS: Inflammatory myofibroblastic tumor of the urinary bladder in a 27-year-old woman with systemic lupus erythematosus. Int J Urol. 2008, 15: 182-184. 10.1111/j.1442-2042.2007.01967.x.PubMedView ArticleGoogle Scholar
- Li HB, Xu YM, Yu JJ: Diagnostic puzzle of inflammatory pseudotumor of the urinary bladder: a case report with brief literature review. South Med J. 2010, 103 (6): 563-566. 10.1097/SMJ.0b013e3181de0ecb.PubMedView ArticleGoogle Scholar
- Lekas A, Parasi A, Papathomas TG, Papatsoris AG, Memnonna MR, Deliveliotis C, Chrisofos M, Lazaris AC: Pseudosarcomatous myofibroblastic lesion of the urinary bladder: A rare entity posing a diagnostic challenge and therapeutic dilemma. Diagn Pathol. 2008, 3: 11-10.1186/1746-1596-3-11.PubMedPubMed CentralView ArticleGoogle Scholar
- Chatzidarellis E, Mazaris E, Skolarikos A, Demonakou M, Mitsogiannis I, Mousiou N, Bisas A: Inflammatory Myofibroblastic Bladder Tumor in a Patient with Von Recklinghausen's Syndrome. Case Reports in Medicine. 2010, 4-Article ID 523964. http://dx.doi.org/10.1155/2010/523964Google Scholar
- Rao RN, Ranjan P, Singla N, Pandey R: Inflammatory myofibroblastic tumor of the urinary bladder diagnosed by anaplastic lymphoma kinase immunostaining. Urology Annals. 2012, 4 (2): 115-118. 10.4103/0974-7796.95567.PubMedPubMed CentralView ArticleGoogle Scholar
- Yagnik V, Chadha A, Chaudhari S, Patel K: Inflammatory myofibroblastic tumor of the urinary bladder. Urology Annals. 2010, 2 (2): 78-79. 10.4103/0974-7796.65106.PubMedPubMed CentralView ArticleGoogle Scholar
- Takeshita H, Kawakami S, Okubo Y, Yamamoto S, Yonese J, Fukui I, Kono A, Kurata M, Inoshita N, Ishikawa Y: A case of inflammatory myofibroblastic tumor of the urinary bladder finally diagnosed by anaplastic lymphoma kinase (ALK) immunostaining. Acta Urologica Japonica. 2006, 52 (5): 375-8.PubMedGoogle Scholar
- Marte A, Indolfini P, Fiociello C, Russo D, Oreste M, Bottigliero G, Gualdiero G, Barone C, Vigliar E, Indolfi C, Casale F: Inflammatory Myofibroblastic Bladder Tumor in a Patient with Wolf- Hirschhorn Syndrome. Case reports in Urology. 2013, 4-doi:10.1155/2013/675059. http://dx.doi.org/10.1155/2F2013/2F675059, ID 675059
- Roth JA: Reactive pseudosarcomatous response in urinary bladder. Urology. 1980, 16: 635-637. 10.1016/0090-4295(80)90578-6.PubMedView ArticleGoogle Scholar
- Karnak I, Senocak M, Cifci A, Caglar M, Bingol-Kologlu M, Tanyel F, Buyukpamukcu N: Inflammatory myofibroblastic tumors in children: diagnosis and treatment. J Pediatric Surg. 2001, 36: 908-912. 10.1053/jpsu.2001.23970.View ArticleGoogle Scholar
- Fangusaro J, Klopfenstein K, Groner J, Hammond S, Altura RA: Inflammatory myofibroblastic tumor following hematopoetic stem cell transplantation: report of two pedriatric cases. Bone Marrow Transplant. 2004, 33: 103-107. 10.1038/sj.bmt.1704292.PubMedView ArticleGoogle Scholar
- Coffin CM, Fletcher JA: Inflammatory myofibroblastic tumor. World Health Organisation Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Edited by: Fletcher CDM, Unni KK, Mertens F. 2000, Lyon: IARC Press, 91-93.Google Scholar
- Coffin CM, Hornick JL, Fletcher CDM: Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol. 2007, 31: 509-520. 10.1097/01.pas.0000213393.57322.c7.PubMedView ArticleGoogle Scholar
- Idrissi- Serhrouchni K, El-Fatemi H, El Madi A, Benhayoun K, Chbani L, Harmouch T, Bouabdellah Y, Amarti A: Primary renal teratoma: a rare entity. Diagn Pathol. 2013, 8: 107-10.1186/1746-1596-8-107.PubMedPubMed CentralView ArticleGoogle Scholar
- Saini M, Krishnamurthy S, Kumar RV: Intrapulmonary mature teratoma. Diagn Pathol. 2006, 1: 46-10.1186/1746-1596-1-46.PubMedPubMed CentralView ArticleGoogle Scholar
- Ayhan A, Bukumulez O, Genc C, Karamursel BS, Ayhan A: Mature cystic teratomas of the ovary: case series from one institiution over 34 years. Eur J Obstet Gynecol Reprod Biol. 2000, 88: 153-157. 10.1016/S0301-2115(99)00141-4.PubMedView ArticleGoogle Scholar
- Ding Y, Gu X-Y, Xu F: at all. MicroRNA expression profiling of mature ovarian teratomas. Oncology Letters. 2012, 3: 35-38.PubMedPubMed CentralGoogle Scholar
- Harik LR, Merino C, Coindre JM, Amin MB, Pedeutour F, Weiss SW: Pseudosarcomatous myofibroblastic proliferations of the bladder: a clinicopathologic study of 42 cases. Am J Surg Pathol. 2006, 30: 787-794. 10.1097/01.pas.0000208903.46354.6f.PubMedView ArticleGoogle Scholar
- Iczkowski KA, Shanks JH, Gadaleanu V, Cheng L, Jones EC, Neumann R, Nascimento AG, Bostwick DG: Inflammatory pseudotumor and sarcoma of urinary bladder: differential diagnosis and outcome in thirty-eight spindle cell neoplasms. Mod Pathol. 2001, 14: 1043-1051. 10.1038/modpathol.3880434.PubMedView ArticleGoogle Scholar
- Singer AJ, Apple SK: Inflammatory pseudotumor of the urinary bladder. Infect Urol. 2001, 14: 68-74.Google Scholar
- Solomon GJ, Kinkhabwala MM, Akhtar M: Inflammatory myofibroblastic tumor of the liver. Arch Pathol Lab Med. 2006, 130: 1548-1551.PubMedGoogle Scholar
- Cessna MH, Zhou H, Sanger WG, Perkins SL, Tripp S, Pickering D, Daines C, Coffin CM: Expression of ALK1 and p80 in Inflammatory Myofibroblastic Tumor and Its Mesenchymal Mimics: A Study of 135 Cases. Mod Pathol. 2002, 15 (9): 931-938. 10.1097/01.MP.0000026615.04130.1F.PubMedView ArticleGoogle Scholar
- Sukov WR, Cheville JC, Carlson AW, Shearer BM, Piatigorsky EJ, Grogg KL, Sebo TJ, Sinnwell JP, Ketterling RP: Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. Mod Pathol. 2007, 20: 592-603. 10.1038/modpathol.3800776.PubMedView ArticleGoogle Scholar
- Ziarkiewicz-Wróblewska B, Górnicka B, Gierej B, Suleiman W, Nowacka-Cieciura E, Durlik M, Bogdańska M, Wasiutyński A, Pileri SA: Hodgkin-like lymphoma, simulating anaplastic large cell lymphoma in the patient after renal transplantation--unusual case report and literature review. Pol J Pathol. 2008, 59 (1): 63-9.PubMedGoogle Scholar
- Dąbroś W, Adamczyk A, Ciurkot K, Kordowiak AM: Vanadium compounds affect growth and morphology of human rhabdomyosarcoma cell line. Pol J Pathol. 2011, 4: 262-268.Google Scholar
- Albayrak F, Dursun H, Albayrak Y, Atlas S, Uyanik A, Yildirim R: Inflammatory myofibroblastic tumor of the stomach in an adult woman: a rare intermittent cause of gastric outlet obstruction. Tumori. 2010, 96: 492-495.PubMedGoogle Scholar
- Poon KS, Moreira O, Jones EC, Treissman S, Gleave ME: Inflammatory pseudotumor of the urinary bladder: a report of five cases and review of the literature. Can J Urol. 2001, 8: 1409-1415.PubMedGoogle Scholar
- Cheng L, Foster SR, MacLennan GT, Lopez-Beltran A, Zhang S, Montironi R: Inflammatory myofibroblastic tumors of the genitourinary tract- single entity or continuum?. J Urol. 2008, 180 (4): 1235-40. 10.1016/j.juro.2008.06.049.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.